Structure and stereochemistry of the active metabolite of clopidogrel. - Wikidata - wikimedia - TriplyDB

Structure and stereochemistry of the active metabolite of clopidogrel.

Structure and stereochemistry of the active metabolite of clopidogrel.

http://www.wikidata.org/entity/Q34155007

about

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts P2Y12-ADP receptor antagonists: Days of future and past Current perspectives in NSAID-induced gastropathy Resistance to antiplatelet drugs: current status and future research Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1 Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry Implementing genotype-guided antithrombotic therapy.Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.Synergistic effects of clopidogrel and fufang danshen dripping pills by modulation of the metabolism target and pharmacokinetics Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier.Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.Circulating primers enhance platelet function and induce resistance to antiplatelet therapy.Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma?Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study.Minimising the potential for metabolic activation in drug discovery.Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.Clopidogrel resistance--the cardiologist's perspective.Drug evaluation of clopidogrel in patients with ischemic stroke.CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance Clopidogrel resistance: pharmacokinetic or pharmacogenetic?Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Limitations of current therapies to prevent thrombosis: a need for novel strategies.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

P2860

Q24675155-B3A3F4EC-8BB1-4A87-A1F9-E2F26ED10BC4 Q26745619-909AA048-4DFA-497C-9617-5C8EAACDE6CC Q26827673-F7870345-0A52-424E-A6B4-4CCD77572A00 Q28192298-F7B2C1A5-C02C-493D-942D-5A4879C45596 Q28218790-FF039451-F75D-4D68-9505-A8E3B05D18A7 Q30840104-0A2B7CD8-25AB-4343-B011-6ECDFF3A6589 Q33637824-3A6130BB-CDCA-406F-A3DA-926BA4C136C6 Q33666595-2B960D8A-FE5E-4050-8132-7593B4DDEEBE Q33990428-1A513116-8D6B-48EA-B219-C802E6CA9F18 Q34023143-5A9792CB-CCFF-47E6-9D0D-00B217501A44 Q34160457-A3F1816C-2BA1-424A-8B34-DC0F944C0847 Q34339780-BFDFC524-E455-4F29-8AA5-9F1245EF99FE Q34419173-35B73F61-5405-4231-9320-8F1E7CE5ED61 Q34520795-99D1DE49-91A1-4958-9FE5-57A5B958E57F Q34536091-3123A7F7-9139-4012-AF56-23A77C81F218 Q34659495-8AA32E62-897A-4BF8-9BB6-CDB75C25C8BA Q35415762-CD2E42AF-A042-4255-8978-6558673C0277 Q35605112-29D93EB6-FDEE-461C-8A2A-D17EA6BB54B2 Q35634115-D12B8030-95A0-4F00-8176-D7D2C703A337 Q35752619-B56AA984-D6D3-46AA-804F-B8D7E9959E02 Q35891375-CF1C3E49-60C9-488C-96C1-7F96DBBAD32F Q35981110-DE6ACB09-57F6-4877-8D91-4296D9F52F59 Q36105504-596780FD-3611-4319-A205-1F14CBF39D31 Q36140286-7BBBF0C6-6E7A-47B2-889B-3537BC8FF405 Q36407222-F6861550-2B9B-43F4-A59C-A94258994A23 Q36453529-2103D40E-F82A-41AB-BE59-EDF183665246 Q36572637-8BDC320D-00EE-4D60-B97B-22600B459BC6 Q36717084-445A6652-E88D-4542-BE06-82BD70E0936E Q36819608-45B26262-BADD-4845-B048-D652D55275C9 Q36979338-5BDF19B3-873A-440E-B2BF-7A92A2842F38 Q37078060-E0806529-B9C6-4F20-92E0-E7FF9A4FFD60 Q37204050-E8F964C8-B7AA-44A3-ABA2-7207A2E939DB Q37402214-F45ECCF9-86F3-438A-BDFB-329C2A17B658 Q37498604-F1E29D06-F117-461E-B1AF-5AC392F27B89 Q37506535-7B98CA79-44D8-4D32-895D-5FA0AC83CCF1 Q37540088-DCE02D2F-6A95-4D7B-9ECC-3F158906AABF Q37579228-C23CE752-E792-40CC-9ECC-D44D483ECE35 Q37641606-14329AD5-6BB8-49E3-9EFE-E43DC356C1EC Q37679719-6225261F-6018-43E2-A11D-82C70DB773B5 Q37693951-ACC0DE25-B6C5-4C85-9CD0-C80942D579B3

P2860

Structure and stereochemistry of the active metabolite of clopidogrel.

http://www.wikidata.org/entity/Q34155007

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Structure and stereochemistry of the active metabolite of clopidogrel.

@ast

Structure and stereochemistry of the active metabolite of clopidogrel.

@en

Structure and stereochemistry of the active metabolite of clopidogrel.

@nl

type

label

Structure and stereochemistry of the active metabolite of clopidogrel.

@ast

Structure and stereochemistry of the active metabolite of clopidogrel.

@en

Structure and stereochemistry of the active metabolite of clopidogrel.

@nl

prefLabel

Structure and stereochemistry of the active metabolite of clopidogrel.

@ast

Structure and stereochemistry of the active metabolite of clopidogrel.

@en

Structure and stereochemistry of the active metabolite of clopidogrel.

@nl

P1433

Q34155007-C205B38C-EB67-4E3D-BFD3-D6A85B710562

P1476

Q34155007-7C4BC509-B51F-4FC4-B8DD-7A2122C94D5F

P2093

Q34155007-219B77DB-95E4-40E6-A2E2-8F25E45C146A

Q34155007-27EEE998-FC07-4C4F-B016-01A8F6EFDF4F

Q34155007-763D21BC-19F8-4AF6-B92F-32079444338F

Q34155007-79F36930-E38D-4EDC-80DB-3346D07A5B1B

Q34155007-A5C1734E-3D43-4FB0-9B8F-6823720F6521

Q34155007-B678EE34-1144-4EF7-A826-C092489E2639

Q34155007-C9520E84-D615-4704-96D3-B533FAF38134

Q34155007-D93F484E-EC11-4A74-8FF7-2F6B9D9D3310

Q34155007-EC9015DE-A2D2-4962-9104-1118A2ED8868

Q34155007-F8C2D894-24AA-46C7-AC3F-59CAA1A68812

P304

Q34155007-09241431-4401-4055-989E-08053F80CF5F

P31

Q34155007-15A99675-CD1A-4757-8917-C3D4788D9D3B

P356

Q34155007-5AE7D16B-C48F-4D25-95E9-D75D1EFCA1E8

P433

Q34155007-5523063B-C852-4F80-B6D7-90FF3F93F4BC

P478

Q34155007-47659CCA-7E78-4373-A927-91C59D2D7868

P577

Q34155007-E8B5B9BE-C791-4838-9603-04D39D4922A2

P698

Q34155007-65FCA0B1-3258-4674-96EE-1A5B630D1B4B

P921

Q34155007-DBCF0BA5-B567-45CF-BC8A-8D8C72621024

P356

P1433

Drug Metabolism and Disposition

P1476

Structure and stereochemistry of the active metabolite of clopidogrel.

@en

P2093

Alain Andrieu

http://www.w3.org/2001/XMLSchema#string

Claudine Picard

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Herbert

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Pereillo

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Maffrand

http://www.w3.org/2001/XMLSchema#string

Marc Pascal

http://www.w3.org/2001/XMLSchema#string

Marie-Francoise Uzabiaga

http://www.w3.org/2001/XMLSchema#string

Mohamed Maftouh

http://www.w3.org/2001/XMLSchema#string

Olivier Fedeli

http://www.w3.org/2001/XMLSchema#string

Pierre Savi

http://www.w3.org/2001/XMLSchema#string

P304

1288-1295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.30.11.1288

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12386137

http://www.w3.org/2001/XMLSchema#string

P921